Aktienanalyse zu Uniqure NV (QURE)QUREUniqure NV

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $21.78 and the RSI at 28.754 indicating oversold conditions, this stock is not a good buy right now. The significant drop of 50.50% over the last 20 days and the failure to achieve statistical significance in recent study results raise serious concerns about its future. The main risk is the negative sentiment stemming from the recent 37% drop in share price following disappointing clinical trial data, which has led to downgrades from multiple analysts.

5 analysts cover QURE: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 49.88.